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Abstract
Background: In Switzerland and other developed countries, the number of tuberculosis (TB) cases has been decreasing for
decades, but HIV-infected patients and migrants remain risk groups. The aim of this study was to compare characteristics of
TB in HIV-negative and HIV-infected patients diagnosed in Switzerland, and between coinfected patients enrolled and not
enrolled in the national Swiss HIV Cohort Study (SHCS).
Methods and Findings: All patients diagnosed with culture-confirmed TB in the SHCS and a random sample of culture-
confirmed cases reported to the national TB registry 2000–2008 were included. Outcomes were assessed in HIV-infected
patients and considered successful in case of cure or treatment completion. Ninety-three SHCS patients and 288 patients
selected randomly from 4221 registered patients were analyzed. The registry sample included 10 (3.5%) coinfected patients
not enrolled in the SHCS: the estimated number of HIV-infected patients not enrolled in the SHCS but reported to the
registry 2000–2008 was 146 (95% CI 122–173). Coinfected patients were more likely to be from sub-Saharan Africa (51.5%
versus 15.8%, P,0.0001) and to present disseminated disease (23.9% vs. 3.4%, P,0.0001) than HIV-negative patients.
Coinfected patients not enrolled in the SHCS were asylum seekers or migrant workers, with lower CD4 cell counts at TB
diagnosis (median CD4 count 79 cells/mL compared to 149 cells/mL among SHCS patients, P=0.07). There were 6 patients
(60.0%) with successful outcomes compared to 82 (88.2%) patients in the SHCS (P=0.023).
Conclusions: The clinical presentation of coinfected patients differed from HIV-negative TB patients. The number of HIV-
infected patients diagnosed with TB outside the SHCS is similar to the number diagnosed within the cohort but outcomes
are poorer in patients not followed up in the national cohort. Special efforts are required to address the needs of this
vulnerable population.
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Introduction
Tuberculosis (TB) in patients co-infected with HIV is a major
global public health challenge [1]. HIV infection is the most
important factor increasing the risk of progression from latent
infection with Mycobacterium tuberculosis to clinically active disease
[2]. On the other hand, TB may induce retroviral replication [3].
Highly active antiretroviral combination therapy (ART) has
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e34186substantially improved the prognosis of HIV infection and reduced
the risk of TB both in industrialized and low-income countries.
Nevertheless, in many resource-constrained settings TB remains
the most common acquired immune deficiency syndrome (AIDS)-
defining illness [4].
In Switzerland, the total number of TB cases has been
decreasing for decades, but HIV-infected patients and migrants
remain risk groups [5,6]. HIV coinfection is not included in the
national TB surveillance system, and can only be estimated by the
number of AIDS-defining TB cases [7,8]. Risk factors for TB in
HIV-infected patients include low CD4 cell count, and the
patient’s origin (higher risk in patients originating from Eastern
Europe, sub-Saharan Africa and Brazil compared to other patients
[5]. An analysis of the Swiss HIV Cohort Study (SHCS) showed
that in the ART era 142 (2.3%) of 6,160 patients had a history of
TB at enrolment into the cohort, and 56 (0.9%) developed TB
during follow-up [9]. In countries with a high TB burden CD4 cell
count is a major risk factor for TB [10], but the risk may differ
between communities [11].
In Switzerland, France, The Netherlands and other countries,
HIV-infected patients are followed-up in prospective studies that
have national coverage [12–15]. About 70% of HIV-infected
patients in Switzerland with advanced disease are enrolled in the
SHCS [12]. Patients included in HIV cohort studies may,
however, not be representative of all patients living with HIV in
the country. In particular, little is known about HIV-infected TB
patients who are not enrolled in cohort studies, and about HIV-
infected compared to HIV-negative TB patients.
The aim of this study was to describe the patient characteristics
and treatment outcomes in HIV-infected TB patients enrolled and
not enrolled in the national Swiss cohort, and to compare them to
HIV-negative TB patients.
Methods
The Swiss Molecular Epidemiology of Tuberculosis (SMET)
study is a collaborative project [16] between the SHCS, the
National Center for Mycobacteria, diagnostic microbiology
laboratories, departments of respiratory medicine and public
health, and the Federal Office of Public Health (FOPH). The
overarching aim was to examine the genetic population structure
of M. tuberculosis and the associations between strain variation,
patient origin and clinical characteristics in HIV-infected com-
pared to HIV-negative TB patients. Further information on the
SMET project is available at www.tb-network.ch. All participating
sites are listed in the File S1. The SHCS is a prospective
observational study of HIV-infected individuals undertaken in
HIV outpatient clinics in Switzerland, which has been described in
detail elsewhere [14].
All HIV-infected patients diagnosed with TB in the SHCS
between 2000 and 2008 whose M. tuberculosis complex (MTBC)
isolate was available were retrospectively included in the SMET
study. Both ‘‘incident’’ and ‘‘prevalent’’ TB cases were eligible, i.e.
patients who developed TB during follow-up and patients
diagnosed with TB at enrolment into the SHCS [9]. For each
eligible SHCS patient three culture-confirmed TB cases not
enrolled in the SHCS but reported to the National TB Registry
during the same time period were randomly selected (288 from the
reported 4,221 culture-confirmed TB cases). Notification of all TB
cases in Switzerland, including information on age, sex, date of
birth, geographic origin, legal status, drug resistance is mandatory
in Switzerland, but TB treatment outcomes are not reported.
In HIV-infected patients additional information was obtained
using a standardized questionnaire that was sent to the treating
physicians, including information on TB treatment and outcomes.
TB treatment outcomes were defined according to international
standards [17–19]. Treatment outcomes were further grouped into
three categories: ‘‘successful’’ included cure and treatment
completion; ‘‘unsatisfactory’’ included treatment failure, treatment
interruption, transfer-out and unknown; and ‘‘death’’ of any cause
while on treatment [17]. Drug resistance was defined as any
resistance to isoniazid, rifampicin or ethambutol as reported to the
TB registry.
Differences between groups in binary variables were tested
using x2 tests or Fisher’s exact tests, continuous variables by
Wilcoxon rank sum test. Binomial 95% confidence intervals (CI)
were calculated where appropriate. All analyses were performed in
Stata version 11.1 (Stata Corporation, College Station, TX).
The study was approved by the Ethics Committee of the
University of Bern, Switzerland. Written informed consent was
obtained from all patients enrolled in the SHCS. For patients
outside the SHCS, informed consent was obtained by the treating
physicians. In some cases informed consent could not be obtained
from the patient because he or she could not be located or was
known to have died. For these cases we obtained permission from
the Federal expert commission on confidentiality in medical
research to use the data provided by the treating physician.
Results
In the SHCS 144 definite (culture-confirmed) TB cases were
diagnosed during the study period 2000–2008. Among these, 93
cases (64.6%) had an MTBC isolate available from the strain
collections and were included in the study. The TB registry
included 4,221 culture-confirmed cases. A total of 288 cases were
randomly selected (approximately three cases for every SHCS case
with an available MTBC isolate). The sample included 10 (3.5%)
HIV-infected patients not enrolled in the SHCS. Based on the
proportion of HIV-infected patients in the randomly selected
registry sample and its binomial confidence interval (2.9%–4.1%),
it can be estimated that 146 (95% CI 122–173) HIV-infected
patients not enrolled in the SHCS were among the TB cases
reported to the registry 2000–2008.
Data on a total of 381 TB patients were analyzed, including 103
(26.3%) HIV-infected patients. Table 1 compares socio-demo-
graphic and clinical characteristics between HIV-infected and
HIV-negative TB patients, and of HIV-infected patients enrolled
and not enrolled in the SHCS. The groups were similar regarding
age and sex, but HIV-infected patients were less likely to have
cavitary disease and more likely to have disseminated disease than
HIV-negative patients. HIV-infected patients were also more
likely to have been born in sub-Saharan Africa (51.5% versus
15.8%, p,0.0001). The proportion of patients with multidrug
resistance was higher in HIV-infected patients compared to HIV-
negative patients (1.9% versus 0%) but this failed to reach
conventional statistical significance (p=0.07 by Fisher’s exact test).
Among HIV-infected TB patients the most likely sources of
HIV infection were heterosexual transmission (59, 57.3%),
injecting drug use (13, 12.6%) and men having sex with men
(10, 9.7%). HIV-infected TB patients were most frequently from
sub-Saharan Africa. Median time since immigration from sub-
Saharan Africa until TB diagnosis was 3.3 years (interquartile
range [IQR] 0.8–5.6). The 10 patients not enrolled in the SHCS
included four asylum seekers or refugees, two migrant workers,
three other foreigners (visitors, students, etc.), and one patient with
unknown legal status. Four of the 10 patients were diagnosed in
Geneva. Patients not enrolled in the cohort were younger than
SHCS patients and had lower CD4 cell counts at TB diagnosis
HIV/TB in a Low-Incidence Country
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Table 1). Of the 93 SHCS patients, 36 (38.7%) were diagnosed
with TB while on ART. ART was initiated in all patients, with a
median delay of 5 weeks (IQR 0–12.9) after TB diagnosis among
those not yet on ART.
Outcomes of TB treatment in the 103 HIV-infected patients
are summarized in Figure 1. Overall, TB treatment was successful
in 88 (85.4%) patients and unsatisfactory in 8 patients (7.8%); 7
patients (6.8%) died. A total of 39 patients (37.9%) completed
treatment, in 49 (47.6%) cure was documented and five patients
(4.9%) were transferred. One patient experienced treatment
failure, one interrupted treatment, and the treatment outcome
was unknown in another case. Treatment outcome was poorer in
patients not enrolled in the SHCS: there were 6 patients (60.0%)
with successful outcomes compared to 82 (88.2%) patients among
SHCS participants (p=0.023 by Fisher’s exact test). Among the
seven deaths, three were documented to be TB-related; the other
deaths were due to other reasons or not ascertained. Fifty-six
patients (54.4%) were treated with a standard treatment regimen
including isoniazid (H), rifampicin (R), ethambutol (E), and
pyrazinamide (Z); H/Z/E plus Rifabutin was used in 19 cases
(18.4%), and H/R/Z/E plus one additional antituberculosis
drug was used in 10 cases (9.7%), and in 18 (17.5%) cases another
non-standard regimen was used.
Table 1. Comparisons of patient characteristics between HIV-infected and HIV-negative tuberculosis patients, and HIV-infected
tuberculosis patients enrolled and not enrolled in the Swiss HIV Cohort Study (SHCS).
Characteristic HIV-infected patients (n=103)
HIV-negative
patients (n=278) P values
All
Non-SHCS
(n=10) SHCS (n=93) All
HIV-infected versus
HIV-negative
SHCS versus
non-SHCS
Age, median (IQR), years 36 (32–45) 33 (28–41) 37 (33–45) 41 (28–63) 0.037 0.21
Male sex, n (%) 49 (47.6) 5 (50.0) 44 (47.3) 139 (50.0) 0.67 0.87
Cavitary disease, n (%) 11 (10.7) 0 (0) 11 (11.8) 62 (22.3) 0.010 0.25
Clinical manifestation, n (%)
Pulmonary 71 (68.9) 7 (70.0) 64 (68.8) 205 (73.7) 0.35 1.0
3
Extra-pulmonary 32 (31.1) 3 (30.0) 29 (31.2) 73 (26.3) 0.35 1.0
3
Disseminated 24 (23.3) 5 (50.0) 19 (20.4) 13 (4.7) ,0.0001 0.050
3
Birth origin, n (%) ,0.0001 1.0
3
Switzerland 25 (24.3) 1 (10.0) 24 (25.8) 70 (25.2)
Europe (without Switzerland) 10 (9.7) 1 (10.0) 9 (9.7) 75 (27.0)
Asia 11 (10.7) 1 (10.0) 10 (10.8) 66 (23.7)
Sub-Saharan Africa 53 (51.5) 5 (50.0) 48 (51.6) 44 (15.8)
Central/South America 3 (2.9) 2 (20.0) 1 (1.1) 10 (3.6)
Other regions/unknown 1 (1.0) 0 1 (1.1) 13 (4.7)
Any drug resistance
1, n (%) 11 (10.7) 1 (10.0) 10 (10.8) 17 (6.1) 0.13 1.0
3
Multidrug resistance, n (%) 2 (1.9) 0 2 (2.2) 0 (0) 0.073
c 1.0
3
CD4 cell count
2, median (IQR), cells/ml 148 (66–280) 79 (14–203) 149 (72–284) - - 0.071
HIV RNA viral load
2, median (IQR), copies/ml 112,800
(11,400–295,000)
196,813
(24,900–327000)
99,503
(7,050–259,000)
- - 0.46
95% CI, 95% confidence interval; IQR, interquartile range.
1Any drug resistance to isoniazid, rifampicin or ethambutol as reported to the Federal Office of Public Health.
2At the time of TB diagnosis.
3Fisher’s exact test.
doi:10.1371/journal.pone.0034186.t001
Figure 1. Summary categories of treatment outcomes in HIV-
infected TB patients enrolled in the Swiss HIV Cohort Study
(SHCS) and not enrolled in the SHCS (non-SHCS). Successful
outcomes included cure and treatment completed; unsatisfactory
outcomes treatment failure, interruption and transfer-out. Overall, only
one patient with treatment failure was reported. Bars add to 100%.
P value from Fisher’s exact tests.
doi:10.1371/journal.pone.0034186.g001
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In this nation-wide study of HIV-infected and HIV-negative TB
patients we found that the two groups were similar with respect to
age and sex, and in both groups about a quarter of patients were
born in Switzerland. The geographic origin of HIV-infected
patients differed: the majority of HIV-infected TB patients were
from sub-Saharan Africa, the region most heavily affected by HIV.
As previously described for developing and industrialized countries
[20,21], cavitary disease was less frequent and disseminated
disease more frequent among HIV-infected patients.
The SHCS has national coverage, but the cohort does not
appear to be representative of all HIV-infected TB patients. Our
random sample from the national TB registry identified 10 HIV-
infected patients not enrolled in the SHCS. It can thus be
estimated that about 146 additional HIV-infected TB patients not
enrolled in the SHCS were diagnosed during the study period. We
found that these patients were a vulnerable, marginalized group
of immigrants and asylum seekers with poor TB treatment out-
comes. TB treatment outcomes among HIV-infected patients
were satisfactory overall: the 85% successful treatments compare
favorably with other European countries for which success rates
(regardless of HIV status) of 70% to 80% have been reported [22].
In particular, transfer-outs were more frequent in the non-cohort
patient group, whereas patients with treatment failure were rare
(one patient only).
We found that outcomes of HIV-infected TB patients are
poorer in patients not followed up in the national cohort. Our
results suggest that enrolment in the SHCS may have a beneficial
effect on treatment outcomes, or alternatively that patients who
agreed to enroll in the SHCS may have better health and be more
health conscious than other patients. This finding is consistent
with a previous analysis of the SHCS which showed that patients
who were seen regularly in the cohort from early stages of the
infection were, at comparable levels of immunodeficiency, less
likely to progress to AIDS, and mortality was reduced [23].
Similarly, a study from Birmingham, Alabama, found that patients
who missed visits after initiating outpatient treatment for HIV
infection were at higher risk of death compared with patients who
attended all scheduled appointments [24]. A recent study from the
SHCS found that non-Europeans, particularly from sub-Saharan
Africa, were less likely to participate in the SHCS compared to
Europeans [25].
Of note, four out of 10 HIV-infected TB patients from outside
the SHCS were diagnosed in Geneva. Geneva has the highest
incidence of TB in the country, which is probably explained by the
relatively large number of undocumented migrants living in the
area [21,26]. Since 1996, a mobile outpatient unit has offered
free health care to this population, with excellent uptake [21,26].
There are several possible reasons why these patients were not
enrolled in the SHCS after HIV infection was diagnosed: patients
may be reluctant to engage with more formal health structures
or may be unable to do so due to their fragile socio-economic
situation, and physicians may not ask patients to enroll in the
cohort because of the patients’ uncertain situation or language
barriers.
Our study has several limitations. We analyzed a small sample
of HIV-infected TB patients from outside the SHCS only, who
were identified in the random sample drawn from the national
TB registry. Unfortunately, the registry cannot be linked to the
mandatory, anonymous reports of HIV infections, both for
practical and legal reasons. However, the non-SHCS cases were
obtained from a random sample of all culture-confirmed TB
cases notified to the National TB Registry during the study
period which allowed us to estimate the total number of non-
SHCS TB cases. In addition, we included only patients with
available MTBC isolates, which excluded culture-negative TB
cases. Finally, outcome analysis of TB treatment was limited to
HIV-infected patients.
In conclusion, our findings indicate that in Switzerland a
sizeable group of vulnerable HIV-infected migrants with TB
may not receive optimal care and follow-up. Special efforts are
required to address the needs of this population.
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